5%). Median follow up was 6.7 years.
Elastin % area was significantly ACP-196 associated with the time to a clinical outcome in univariate analysis (p=0.011). We used median elastin % area as a threshold (2.96%) to stratify the cohort and found that those with higher elastin progressed to outcomes more quickly (Fig 1). There was no difference in time to clinical outcomes between those with IS5 and IS6 fibrosis. Quantification of hepatic elastin using immunostaining and automated image analysis is feasible and could be a useful addition to standard histopathological assessment of fibrosis as a tool for stratifying clinical progression in cirrhosis. This could influence intensity of surveillance and timing of referral for transplant. Disclosures: William Irving – Advisory Committees or Review Panels: Novartis, MSD, Janssen
Cilag, Novartis, MSD, Janssen Cilag; Consulting: GlaxoSmithKline, Glaxo-SmithKline; Grant/Research Support: GSK, Pfizer, Janssen Cilag, GSK, Pfizer, Janssen Cilag Indra Neil Guha – Grant/Research Support: Pfizer, Conatus The following people have nothing to disclose: Grace E. Dolman, Jie Shu, Guoping Qiu, Claire Hawkes, Abed Zaitoun, Jonathan Fallowfield Background & Aims: Mac-2BP glycoprotein is involved in the immune defense against a variety of neoplasms and viral infections, modulating the activity of several effectors such as natural killer cells. Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA(+)-M2BP) was recently
validated RG 7204 as a liver fibrosis glycobiomarker, which was a unique fibrosis-related glyco-alteration (Kuno A et.al. Scientific reports 201 3). And this novel marker is available for clinically beneficial therapy evaluation through quantification of disease severity. We evaluated the utility of WFA(+)-M2BP to predict the development Sulfite dehydrogenase of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection. Methods: A total of 707 patients with chronic HCV infection without the other risks were evaluated for the predictive value of the development of HCC, including age, sex, viral load, genotypes, fibrosis stage, aspartate and alanine aminotransferase levels, bilirubin, albumin, platelet count, alpha-fetoprotein (AFP) and WFA(+)-M2BP at the entry, as well as interferon therapy they received. All patients received the examination of liver biopsy. WFA(+)-M2BP quantification was measured with a fully automated lectin-antibody sandwich immunoassay. Results: Serum WFA(+)-M2BP levels had a significant correlation with the degree of liver fibrosis stage (p < 0.001). The 10-year cumulative risk of the development of HCC was 1.1 % in the patients with WFA(+)-M2BP < 1 cutoff index (COI) at the study entry, 14.8% in the patients with WFA+-M2BP 1-4 COI, and 54.1% in the patients with WFA(+)-M2BP > 4 COI (P < 0.001) . The cumulative incidence of HCC stratified by the fibrosis stage, were significantly higher according to WFA(+)-M2BP level.
Related posts:
- 3% Likewise
the AUROC of vascular diverging angle for di - The median TTP was 137 5 days 84 Vatalanib is an oral TKI which targets VEGFRs,
- 3 years in patients wild type for both Our cohort included 22 pa
- 4-6 9) kPa, in association with the reduction of ALT levels (Figu
- There were 44 patients with biopsy-proven NASH